Anti-Hu CD19 FITC
CAT:
270-1F-305-T100
Size:
100 Tests
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

Anti-Hu CD19 FITC
- Background: CD19 is a transmembrane glycoprotein of Ig superfamily expressed by B cells from the time of heavy chain rearrangement until plasma cell differentiation. It forms a tetrameric complex with CD21 (complement receptor type 2), CD81 (TAPA-1) and Leu13. Together with BCR (B cell antigen receptor), this complex signals to decrease B cell treshold for activation by the antigen. Besides being signal-amplifying coreceptor for BCR, CD19 can also signal independently of BCR coligation and it turns out to be a central regulatory component upon which multiple signaling pathways converge. Mutation of the CD19 gene results in hypogammaglobulinemia, whereas CD19 overexpression causes B cell hyperactivity.
- Specifications: The antibody LT19 reacts with an extracellular epitope of CD19 (B4), a 95 kDa type I transmembrane glycoprotein (immunoglobulin superfamily) expressed on B lymphocytes and follicular dendritic cells it is lost on plasma cells.
- Certification: RUO
- Host: Mouse
- Species Reactivity: Human
- Immunogen: Daudi human Burkitt lymphoma cell line
- Target Antigen: CD19
- Isotype: IgG1
- Clone: LT19
- Applications: Flow cytometry: The reagent is designed for analysis of human blood cells using 20 μl reagent / 100 μl of whole blood or 106 cells in a suspension. The content of a vial (2 mL) is sufficient for 100 tests.
- Validated Applications: FC
- Format: FITC
- Buffer: Stabilizing phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
- References & Citations: *Lin CW, Liu TY, Chen SU, Wang KT, Medeiros LJ, Hsu SM: CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features. Blood. 2005 Nov 15106(10):3567-74. Epub 2005 Jul 26., URL: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=AbstractPlus&list_uids=16046525&query_hl=14&itool=pubmed_DocSum ,*Stehlíková O, Chovancová J, Tichý B, Krejčí M, Brychtová Y, Panovská A, Francová Skuhrová H, Burčková K, Borský M, Loja T, Mayer J, Pospíšilová S, Doubek M: Detecting minimal residual disease in patients with chronic lymphocytic leukemia using 8-color flow cytometry protocol in routine hematological practice. Int J Lab Hematol. 2013 Sep 13. doi: 10.1111/ijlh.12149., URL: http://www.ncbi.nlm.nih.gov/pubmed/24028768 ,*Kayserova J, Vcelakova J, Stechova K, Dudkova E, Hromadkova H, Sumnik Z, Kolouskova S, Spisek R, Sediva A: Decreased dendritic cell numbers but increased TLR9-mediated interferon-alpha production in first degree relatives of type 1 diabetes patients. Clin Immunol. 2014 Jul153(1):49-55., URL: http://www.ncbi.nlm.nih.gov/pubmed/24709112 ,*Elias F, Flo J, Lopez RA, Zorzopulos J, Montaner A, Rodriguez JM: Strong cytosine-guanosine-independent immunostimulation in humans and other primates by synthetic oligodeoxynucleotides with PyNTTTTGT motifs. J Immunol. 2003 Oct 1171(7):3697-704. , URL: https://www.ncbi.nlm.nih.gov/pubmed/14500668?dopt=,*Allen JS, Pang K, Skowera A, Ellis R, Rackham C, Lozanoska-Ochser B, Tree T, Leslie RD, Tremble JM, Dayan CM, Peakman M: Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes. 2009 Jan58(1):138-45., URL: https://pubmed.ncbi.nlm.nih.gov/18835928/,
- Other References: *Shi X, Xie C, Chang S, Zhou XJ, Tedder T, Mohan C: CD19 hyperexpression augments Sle1-induced humoral autoimmunity but not clinical nephritis. Arthritis Rheum. 2007 Sep56(9):3057-69., URL: https://pubmed.ncbi.nlm.nih.gov/17763445/,*van Zelm MC, Reisli I, van der Burg M, Castaño D, van Noesel CJ, van Tol MJ, Woellner C, Grimbacher B, Patiño PJ, van Dongen JJ, Franco JL: An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med. 2006 May 4354(18):1901-12., URL: https://pubmed.ncbi.nlm.nih.gov/16672701/,*Inabe K, Kurosaki T: Tyrosine phosphorylation of B-cell adaptor for phosphoinositide 3-kinase is required for Akt activation in response to CD19 engagement. Blood. 2002 Jan 1599(2):584-9., URL: https://pubmed.ncbi.nlm.nih.gov/11781242/,*Fujimoto M, Poe JC, Jansen PJ, Sato S, Tedder TF: CD19 amplifies B lymphocyte signal transduction by regulating Src-family protein tyrosine kinase activation. J Immunol. 1999 Jun 15162(12):7088-94., URL: https://pubmed.ncbi.nlm.nih.gov/10358152/,
- Storage Conditions: Store at 2-8°C. Protect from prolonged exposure to light. Do not freeze.